Fig. 3From: Comparison of the efficacy and safety of Transarterial chemoembolization with and without Apatinib for the treatment of BCLC stage C hepatocellular carcinomaOverall survival(OS) curves of patients with unresectable hepatocellular carcinoma in the two groups. The median survival period in the Apatinib+TACE group was significantly longer than that of the TACE alone group (OS: 13.0 vs 9.9 months, P = 0.041)Back to article page